Dendritic cell-based cancer immunotherapy
Aruga, A.
Nihon Rinsho. Japanese Journal of Clinical Medicine 68(6): 1107-1110
2010
ISSN/ISBN: 0047-1852 PMID: 20535963 Document Number: 638990
Dendritic cell is the most effective antigen presenting cells in human. We performed a couple of dendritic cell-based cancer immunotherapy in Tokyo Women's Medical University. Autologous tumor lysates or synthetic peptides are pulsed with dendritic cells to make the dendritic cell vaccine. Tumor-pulsed dendritic cell vaccine (TP-DC) or peptide pulsed dendritic cell vaccine (PP-DC) are safe and useful in the patients with advanced cancer. Antigen unpulsed immature dendritic cell could work at a cancer vaccine when they inject into tumors in vivo. Dendritic cell-activated T cells (DCAT) in vitro are also useful tools for cancer treatment. In order to obtain a good evidence of dendritic cell-based immunotherapy, we need to perform the randomized trial near the future.